Výsledky vyhledávání - "William D. Fox"

Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARγ

Autor: William D. Fox, Desheng Lu, Michael Hedvat, Stuart Holden, David B. Agus, Ganghua Huang, Dennis A. Carson, Lorenzo M. Leoni, Maripat Corr, Anjali Jain

Publikováno v: Cancer Cell. 5:565-574

R-etodolac, a nonsteroidal anti-inflammatory drug, inhibits the progression of CWRSA6 androgen-independent and LuCaP-35 androgen-dependent prostate cancer xenograft growth through downregulation of cyclin D1 expression via the PPARgamma pathway. PPAR

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be66fa75abb19b203a6d3f93dab92157
https://doi.org/10.1016/j.ccr.2004.05.014

Zobrazit plný text záznamu

CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts

Autor: William D. Fox, David F. Duncan, Jason Brown, Edwin L. Madison, Ofir Moreno, Anna Galkin, David B. Agus, Lynne Mullen

Publikováno v: The Prostate. 61:228-235

BACKGROUND Matriptase, a type-II transmembrane serine protease, is expressed by cancers of epithelial origin including breast, colon, and prostate carcinomas and has been implicated in tumor growth and progression. We studied the effects of CVS-3983,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e46b20332d064c699632a9bb576f2d24
https://doi.org/10.1002/pros.20094

Zobrazit plný text záznamu

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

Autor: David B. Agus, Robert W. Akita, Julie A. Lofgren, Brian Higgins, Mark X. Sliwkowski, Gail D. Lewis, Paul I. Pisacane, Douglas P Evans, Charles A. Tindell, William D. Fox, Howard I. Scher, Krista Maiese

Publikováno v: Cancer Cell. 2(2):127-137

ErbB2 is a ligand-less member of the ErbB receptor family that functions as a coreceptor with EGFR, ErbB3, and ErbB4. Here, we describe an approach to target ErbB2's role as a coreceptor using a monoclonal antibody, 2C4, which sterically hinders ErbB

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ae0de7bffb4f4f6d1948d13b3e50863

Zobrazit plný text záznamu

Dehydroascorbic acid, a blood–brain barrier transportable form of vitamin C, mediates potent cerebroprotection in experimental stroke

Autor: David J. Pinsky, J. Mocco, Judy Huang, Tanvir F. Choudhri, William D. Fox, David B. Agus, David W. Golde, Robert J. Israel, William J. Mack, Ryan A McTaggart, Thomas A. Boyd, E. Sander Connolly, Szilard Kiss, Christopher J. Winfree, Louis J. Kim

Publikováno v: Proceedings of the National Academy of Sciences. 98:11720-11724

Neuronal injury in ischemic stroke is partly mediated by cytotoxic reactive oxygen species. Although the antioxidant ascorbic acid (AA) or vitamin C does not penetrate the blood–brain barrier (BBB), its oxidized form, dehydroascorbic acid (DHA), en

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29e8fcacd9fcaf8cae3a5713d10b4383
https://doi.org/10.1073/pnas.171325998

Zobrazit plný text záznamu

Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer

Autor: William D, Fox, Brian, Higgins, Krista M, Maiese, Marija, Drobnjak, Carlos, Cordon-Cardo, Howard I, Scher, David B, Agus

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 8(10)

Human tumors are dependent on angiogenesis for growth, and vascular endothelial growth factor (VEGF) is a major regulator of this process. We aimed to study clinical utility of a recombinant humanized monoclonal anti-VEGF antibody (rhu alpha VEGF) in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a056ccd5d9604b5bb065f8520d32112d
https://pubmed.ncbi.nlm.nih.gov/12374693

Zobrazit plný text záznamu

Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence

Autor: Marija Drobnjak, David W. Golde, David B. Agus, Howard I. Scher, Carlos Cordon-Cardo, Andrew Koff, William D. Fox

Publikováno v: Journal of the National Cancer Institute. 91(21)

Background Androgen withdrawal is a standard therapy for prostate cancer that results in a decrease in tumor volume and a decline in serum prostate-specific antigen in the majority of patients. To understand the factors associated with regression of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1913b2a905898bb8c674cd7c8ee5a63
https://pubmed.ncbi.nlm.nih.gov/10547394

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání